Related Experiment Video
Updated: Aug 8, 2026
11:09
Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
Published on: August 1, 2018
Structure-guided design of peptide-based tryptase inhibitors
Mary E McGrath1, Paul A Sprengeler, Bernard Hirschbein
1Celera Genomics, Inc., 180 Kimball Way, South San Francisco, California 94080, USA. mary.mcgrath@gilead.com
Biochemistry
|May 10, 2006
Summary
Researchers developed novel peptide inhibitors for human beta tryptase, improving potency and selectivity. These new inhibitors replace traditional elements without sacrificing target affinity, offering a promising therapeutic avenue.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Human beta-tryptase is a key mediator in allergic inflammatory responses.
- Existing peptide-based inhibitors often rely on Lysine (Lys) or Arginine (Arg) at the P1 position.
- Optimization is needed to enhance potency and selectivity of tryptase inhibitors.
Purpose of the Study:
- To discover improved peptide-based inhibitors of human beta-tryptase.
- To explore the replacement of Lys/Arg at the P1 position in peptide inhibitors.
- To achieve high potency and selectivity against the mast cell target.
Main Methods:
- Utilized tripeptide library screening.
- Employed structure-guided design, including fragment screening.
- Synthesized and characterized novel peptide-like compounds.
Main Results:
- Discovered optimized compounds with low nanomolar potency against human beta-tryptase.
- Achieved several hundred-fold selectivity over serine protease off-targets.
- Demonstrated that P1 element replacement is feasible without affinity loss.
Conclusions:
- Novel peptide inhibitors of human beta-tryptase were successfully developed.
- Replacing Lys/Arg at P1 can yield potent and selective inhibitors.
- These findings advance the development of tryptase-targeted therapeutics.
